SCM
CLYM

Silverarc Capital Management’s Climb Bio CLYM Stock Holding History

Silverarc Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.69M Buy
+684,908
New +$3.95M 0.48% 45
2023
Q4 		– Sell
-121,110
Closed -$319K – 90
2023
Q3 		$319K Sell
121,110
-372,979
-75% -$1.02M 0.1% 71
2023
Q2 		$1.38M Buy
494,089
+8,134
+2% +$24.7K 0.43% 51
2023
Q1 		$1.41M Buy
485,955
+76,753
+19% +$264K 0.58% 53
2022
Q4 		$1.5M Buy
409,202
+7,114
+2% +$21.1K 0.43% 59
2022
Q3 		$1.3M Sell
402,088
-310,921
-44% -$992K 0.44% 57
2022
Q2 		$2.15M Buy
713,009
+624,730
+708% +$2.96M 0.66% 39
2022
Q1 		$741 Buy
+88,279
New +$824K 0.31% 56

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Silverarc Capital Management's CLYM Position: Q1 2026 in Review

Silverarc Capital Management opened a new position in Climb Bio (CLYM) in Q1 2026: 684,908 shares worth $4.69M. The stake represents 0.48% of the portfolio and ranks #45 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in CLYM as recently as Q3 2023.

Silverarc Capital Management first reported a position in CLYM in Q1 2022 and has held it in 8 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Silverarc Capital Management held 684,908 shares of Climb Bio worth $4.69M as of Q1 2026.
  • Climb Bio was a new Silverarc Capital Management position in Q1 2026.
  • Climb Bio made up 0.48% of Silverarc Capital Management's portfolio in Q1 2026, its #45 holding.
  • Silverarc Capital Management first reported a position in Climb Bio in Q1 2022 and has held it in 8 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.